Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
217 hedge funds and large institutions have $4.32B invested in Acceleron Pharma in 2020 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 53 increasing their positions, 77 reducing their positions, and 28 closing their positions.
129% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 28
68% more capital invested
Capital invested by funds: $2.57B → $4.32B (+$1.76B)
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
19% more funds holding
Funds holding: 183 → 217 (+34)
14% less call options, than puts
Call options by funds: $54.7M | Put options by funds: $63.9M
31% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$66.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$64.1M |
| 3 |
Alkeon Capital Management
New York
|
+$62.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.6M |
| 5 |
Holocene Advisors
New York
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$79.8M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$60.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$50.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$39.6M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$39.3M |
XLRN Hedge Fund Activity: Q1 2020 in Review
217 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2020, worth a combined $4.32B — up 68% from $2.57B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new XLRN positions and 28 closed out — a net gain of 36 holders — while 53 added to existing stakes and 77 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $66.8M. The largest seller was Deerfield Management, cutting an estimated $79.8M.
- 217 institutional investors held Acceleron Pharma (XLRN) as of Q1 2020, up from 183 in Q4 2019.
- Funds reported $4.32B of Acceleron Pharma stock for Q1 2020, up 68% quarter-over-quarter.
- 64 funds opened new Acceleron Pharma positions in Q1 2020 and 28 closed out, a net change of +36 holders.
- The largest Acceleron Pharma buyer in Q1 2020 was Avoro Capital Advisors, an estimated $66.8M added.
- The largest Acceleron Pharma seller in Q1 2020 was Deerfield Management, an estimated $79.8M sold.
Based on aggregated 13F filings for Q1 2020.